Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

RA: What could be the implications on public health if PCSK9 inhibitors were approved for use? JE: Despite cholesterol-lowering therapy, an estimated 66% of all adults in the US who are treated do ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

In America, heart disease is the No. 1 killer of men and women and the leading cause of death for people of most racial and ...

Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

Researchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar ...

INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

The Indian government has decided to exempt customs duty on 36 life-saving drugs to enhance access to essential treatments ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.